3 completed, 2 terminated, 1 withdrawn. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Terminated 2, Withdrawn 1 |
| Phase 1 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
Follow Regenera Pharma Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) RPh201 Cohort A, Placebo Cohort A, RPh201 Cohort B - Nonarteritic Anterior Ischemic Optic Neuropathy | Phase 2 | Terminated | Regenera Pharma Ltd | 165 | 2018-07-10 | 2020-10-12 |
| A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease RPh201, Placebo - Mild to Moderate Dementia Due to Alzheimer's Disease, With or Without Coexisting Cerebrovascular Disease | Phase 2 | Completed | Regenera Pharma Ltd | 83 | 2018-03-01 | 2020-04-30 |
| Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION). RPh201, Placebo - Non-arteritic Ischemic Optic Neuropathy, Optic Nerve Injuries | Phase 2 | Completed | Regenera Pharma Ltd | 22 | 2014-02-01 | 2020-03-19 |
| A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease RPh201, botanical drug product, Placebo - Healthy Volunteers, Moderate to Severe Alzheimer Patients | Phase 1 / Phase 2 | Completed | Regenera Pharma Ltd | 39 | 2012-01-01 | 2020-03-23 |
| Trial To Evaluate RPh201 In Treatment Of Partial Thickness Burn RPh201, botanical drug product - Second Degree Burn Less Than 5%TBSA, Partial Thickness Burn | Phase 1 / Phase 2 | Withdrawn | Regenera Pharma Ltd | 2011-12-01 | 2016-12-06 | |
| Efficacy of RPh201 Applied Topically for the Treatment of Hard to Heal Chronic Ulcerated Wounds RPh201, botanical drug product - Chronic Wound | Phase 1 / Phase 2 | Terminated | Regenera Pharma Ltd | 4 | 2011-12-01 | 2018-09-04 |
Dementia (2) · Optic Neuropathy, Ischemic (2) · Alzheimer Disease (1) · Optic Nerve Injuries (1) · Venous Insufficiency (1)
Cottonseed Oil (2)
Israel (3) · Canada (2) · United States (1)
Sharon Cohen, MD (2) · Eran Tamir, Dr. (1) · Eyal Winkler, Dr. MD (1) · Janice Faulknor, MD (1) · Leonard A Levin, M.D., Ph.D. (1) · Zvi Segal,, MD (1)